Application of carfilzomib and epirubicin combined medicine to preparation of medicine for treating liver cancer

A technology of epirubicin and carfilzomib, which is applied in the field of medicine, can solve problems that have not yet been reported, and achieve the effect of improving anti-tumor effect and reducing side effects

Inactive Publication Date: 2021-06-08
阿耳法猫(杭州)人工智能生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. It has inhibitory effect on the activity of topoisomerase II (topoisomerase type II), which leads to the disintegration of genomic DNA
[0005] There are no reports on the combined effects of carfilzomib and epirubicin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of carfilzomib and epirubicin combined medicine to preparation of medicine for treating liver cancer
  • Application of carfilzomib and epirubicin combined medicine to preparation of medicine for treating liver cancer
  • Application of carfilzomib and epirubicin combined medicine to preparation of medicine for treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 MTT method to detect the sensitivity of liver cancer cells to carfilzomib and epirubicin

[0022] 1. Experimental materials

[0023] (1) Drugs: carfilzomib, epirubicin.

[0024] (2) Liver cancer cells: human liver cancer cells HEPG2.

[0025] (3) Commercially available MTT kits.

[0026] 2. Experimental grouping

[0027] (1) Carfilzomib group: different concentrations of carfilzomib were used to treat liver cancer cells.

[0028] (2) Epirubicin group: different concentrations of epirubicin were used to treat liver cancer cells.

[0029] 3. MTT method to detect the sensitivity of tumor cells to carfilzomib and epirubicin

[0030] (1) Human hepatoma cells HEPG2 were inoculated into a 96-well plate at a rate of 5000-9000 cells per well. After the cells adhered to the wall, different concentrations of carfilzomib or epirubicin in PBS were added. After culturing for 24 hours, add 10 μl of MTT with a concentration of 5 mg / ml to each well for another 4 hours, t...

Embodiment 2

[0032] Example 2 Effect of Carfilzomib and Epirubicin Combination on the Inhibition Rate of Liver Cancer Cells

[0033] 1. Experimental materials

[0034] (1) Drugs: carfilzomib, epirubicin.

[0035] (2) Liver cancer cells: human liver cancer cells HEPG2.

[0036] (3) Commercially available MTT kits.

[0037] 2. Experimental grouping

[0038] Combination of different concentrations of carfilzomib and epirubicin to treat liver cancer cells.

[0039] 3. MTT method to detect the sensitivity of liver cancer cells to the combination of carfilzomib and epirubicin

[0040] (1) Human hepatoma cells HEPG2 were inoculated into 96-well plates with 5000-9000 cells per well. After the cells adhered to the wall, PBS solutions with different ratios of carfilzomib and epirubicin were added. After culturing for 24 hours, add 10 μl of MTT with a concentration of 5 mg / ml to each well for another 4 hours, then discard the culture solution and add 100 μl of DMSO to each well, and read the abs...

Embodiment 3

[0042] Example 3 Mouse experiment

[0043] 1. Experimental materials

[0044] (1) Drugs: carfilzomib, epirubicin.

[0045] (2) Nude mice aged 4-6 weeks, weighing 18-20g / mouse, male and female.

[0046] 2. Experimental grouping

[0047] (1) Control group: without any treatment.

[0048] (2) Carfilzomib group: Carfilzomib 16 mg / kg was administered orally, once a day.

[0049] (3) Epirubicin group: Epirubicin 60 mg / kg was administered by intragastric administration, once a day.

[0050] (4) Carfilzomib and epirubicin combined group: the doses and administration methods of carfilzomib and epirubicin were the same as those of the above two groups.

[0051] 3. Administration treatment Observe the weight and volume changes of transplanted tumors in mice.

[0052] (1) HEPG2 cells were grown adherently in RPMI-1640 complete medium containing 10% fetal bovine serum at 37°C, 5% CO 2 , Routine culture in a saturated humidity incubator, and passaging once every 2-3 days. Collect an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine, and particularly relates to an application of a carfilzomib and epirubicin combined medicine to preparation of a medicine for treating liver cancer. The application of the carfilzomib and epirubicin combined medicine to preparation of the medicine for treating the liver cancer is provided for the first time, the carfilzomib and the epirubicin have an obvious synergistic effect, the curative effect is effectively improved, the curative effect is more obvious compared with that of a single component, and the killing performance on tumor cells is improved; and the dosage is effectively reduced, so that toxic and side effects are reduced. The combined use of the carfilzomib and the epirubicin can save the cost, the economic burden of patients is reduced, a new way is provided for the prevention and treatment of the liver cancer, and the combined use of the carfilzomib and the epirubicin has wide application prospects in the field of medicine and pharmacology.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of carfilzomib and epirubicin in the preparation of drugs for treating liver cancer. Background technique [0002] Liver cancer is one of the common malignant tumors in my country, which can be divided into two categories: primary and secondary. Liver cancer cells have strong proliferative ability, and tumor nodules can reach more than ten centimeters. At the same time, they are highly metastatic. They can metastasize not only in the liver, but also to extrahepatic tissues. The most common metastases are lungs, and they can also metastasize to adrenal glands, bones, and kidneys. , brain, etc. At present, the treatment methods for liver cancer are still based on surgery, radiotherapy, and chemotherapy, and the curative effect has not yet made breakthrough progress. [0003] Epirubicin (Epirubicin, Epirubicin) is a representative drug among anthracycline antitu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08A61K31/704A61P35/00
CPCA61K31/704A61K38/08A61P35/00A61K2300/00
Inventor 李斌国栋
Owner 阿耳法猫(杭州)人工智能生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap